Rep. Julie Johnson Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Julie Johnson (D-Texas) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on April 1st. The trade occurred in the Representative's "MERRILL LYNCH TAX EFFICIENT CORE" account.

Representative Julie Johnson also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 4/30/2025.
• Sold $1,001 - $15,000 in shares of Blackstone NYSE: BX on 4/22/2025.
• Purchased $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 4/22/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 4/15/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of 3M NYSE: MMM on 4/11/2025.
• Sold $1,001 - $15,000 in shares of DT Midstream NYSE: DTM on 4/7/2025.
• Sold $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 4/7/2025.
• Sold $1,001 - $15,000 in shares of Howmet Aerospace NYSE: HWM on 4/7/2025.
• Sold $1,001 - $15,000 in shares of Carlisle Companies NYSE: CSL on 4/7/2025.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $1.76 during trading on Friday, reaching $151.37. The company had a trading volume of 8,028,893 shares, compared to its average volume of 7,942,195. The company has a fifty day moving average of $156.56 and a two-hundred day moving average of $154.00. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $364.20 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds have recently modified their holdings of the stock. Norges Bank bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. Raymond James Financial Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $1,339,878,000. Nuveen LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $1,369,188,000. GAMMA Investing LLC increased its position in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Barclays lowered their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Raymond James decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $170.88.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.